Table 3.
Logistic regression analysis for predicting CSPCa
| Univariate analysis | Multivariate analysis | ||||||
|---|---|---|---|---|---|---|---|
| OR (95% CI) | P value | OR (95% CI) | P value | ||||
| Age (years) | 1.05 (0.98–1.13) | 0.204 | - | - | |||
| PSA | 1.17 (0.92–1.49) | 0.209 | - | - | |||
| PV (ml) | 0.95 (0.92–0.98) | 0.002* | 0.95 (0.91-1.00) | 0.032* | |||
| PSAD (ng/ml 2 ) | - | - | |||||
| <0.15 | reference | - | - | - | |||
| ≥0.15 | 12.71 (3.31–48.76) | < 0.001* | - | - | |||
| FPSA/TPSA | 0.00 (0.00-0.03) | 0.005* | 0.00 (0.00-0.05) | 0.016* | |||
| SUVmax | 1.50 (1.23–1.83) | < 0.001* | 1.73 (1.33–2.25) | < 0.001* | |||
CSPCa, clinically significant prostate cancer; PSA, prostate-specific antigen; PV, prostate volume; PSAD, prostate-specific antigen density; TPSA, total prostate-specific antigen; FPSA, free prostate-specific antigen; SUVmax, maximum standardized uptake values
* p < 0.05